Natural killer (NK) cells are innate immune cells with the ability to identify and eliminate transformed cells. However, within tumors, many studies have described NK cells as non-functional. The developmental stage of tumor-associated NK cells and how this may relate to functionality has not been explored. We examined the developmental state of NK cells from polyoma middle T antigen (pyMT) transgenic mouse (MMTV-pMT) breast tumors. In pyMT tumors, NK cells were immature as evidenced by their decreased expression of DX5 and their CD27 low CD11b low phenotype. These immature NK cells also had increased expression of NKG2A and expressed low levels of NKp46, perforin, and granzyme B. In contrast, splenic NK cells isolated from the same mice maintained their maturity and their expression of activation markers. To delineate whether the tumor microenvironment directly alters NK cells, we adoptively transferred labeled NK cells and followed their activation status in both the spleen and the tumor. NK cells that arrived at the tumor had half the expression of NKp46 within three days of transfer in comparison to those which arrived at the spleen. In an effort to modify the tumor microenvironment and assess the plasticity of intratumoral NK cells, we treated pyMT tumors with IL-12 and anti-TGF-b. After one week of treatment, the maturity of tumor-associated NK cells was increased; thus, indicating that these cells possess the ability to mature and become activated. A better understanding of how NK cells are modified by the tumor microenvironment will help to develop strategies aimed at bolstering immune responses against tumors.
INTRODUCTION
Natural killer (NK) cells are innate immune effector cells vital in the defense against virally infected or transformed cells 1 . They are set apart from T and B lymphocytes by their ability to lyse target cells without recognition of a specific antigen 2 . In humans and mice, NK cell subsets can be characterized by their unique expression of cell surface markers. The human population of NK cells is made up of the CD56 dim CD16 1 subsets, which represent around 90% of peripheral blood NK cells and have greater cytotoxicity than the CD56 hi CD16 2 subsets, which make up the remaining population. The CD56 hi CD16 2 subsets have been termed immunoregulatory, and while they lack perforin, they are able to make greater amounts of IFN-c, TNF-a, TNF-b, GM-CSF, IL-13, and IL-10 compared to the CD56 dim CD16 1 subsets. It still remains unclear whether the CD56 hi CD16 2 subsets are precursors to CD56 dim CD16 1 NK cells, or whether the CD56 hi population represents an activated or differentiated CD56 dim NK cell subtype. In mice, CD27 delineates the cytotoxic from the immunoregulatory NK cells. CD27 high NK cells produce greater levels of cytokines and possess a higher cytotoxic capacity compared to CD27 low NK cells, which are more tightly regulated and require a higher threshold for activation. While distinct subsets of human and mice NK cells have been identified, there is no direct comparison between the two. For instance, while the CD27 high and the CD56 hi CD16
2 NK cells both reside in the lymph nodes, CD56 hi CD16
2 NK cells are immunoregulatory while the CD27 high population is highly cytotoxic 3, 4 . As with all other cells of the immune system, NK cells are derived from hematopoietic stem cells originating in the bone marrow 3 . NK cell maturation primarily occurs in the bone marrow but has also been found to occur to a lesser extent in the lymph nodes and in secondary lymphoid tissues 4 . Mouse NK cells undergo three main stages of development; they progress from precursors to immature NK cells and finally to mature NK cells 5 . NK cell precursors have been characterized in the bone marrow as CD1221NK1.12DX52. These cells require the cytokine IL-15 for their continuous development 6 . Immature NK cells are mainly characterized by the absence of mature NK cell markers with the exception of TRAIL. Immature TRAIL1 NK cells can further develop into mature TRAIL2 NK cells which gain the expression of DX5 and CD11b, effector molecules such as perforin and granzyme, and an increased ability to secrete IFN-c 7 . The surface expression of CD27 and CD11b can also be used to dissect NK cells into four distinct subsets of maturation 8 . NK cell development was determined by following the progression of EGFP1 NK cells in NK cell-depleted mice and the maturation of NK cells was determined as follows: CD11b low CD27 low R CD11b . CD11b low CD27 low NK cells are the most immature subset displaying the highest rate of homeostatic proliferation and potential for differentiation. Although mouse and human NK cells do not necessarily share the same markers for identification, CD27 and CD11b can be used to identify distinct stages of NK cell development in both the human and mouse 9 . CD27 and CD11b double positive NK cells are considered mature and highly cytotoxic. These cells are able to leave their site of generation and enter the blood and peripheral tissues, patrolling the body for transformed cells.
Once NK cells enter a tumor site, there is a strong body of evidence which suggests that initially, they have the ability to suppress tumor growth 10 . In the Her2/neu model of spontaneous mammary carcinoma, it was shown that NK cells delay tumor formation in a perforin-dependent manner 11 . This delay was most striking at the earliest stages of carcinogenesis and was not prevalent during the later stages of tumor growth. Although NK cells are set up throughout development to be potent killers, their roles can be subverted at the tumor site. Clinical evidence suggests that NK cell dysfunction accompanies human breast cancer progression 12 . Comparison of peripheral blood NK cells to tumor-infiltrating NK cells revealed that within a tumor, NK cells have decreased expression of activating receptors such as NKp30, NKG2D, and DNAM-1 and increased expression of inhibitory receptors such as NKG2A. This altered phenotype at the tumor site correlated with decreased function and cytotoxicity 12 .
Other than their lack of activity, (decreased IFN-c secretion and downregulation of activating receptors), there is little information regarding the stage of NK cell development within tumors. We wondered whether NK cells which infiltrate murine breast tumors attain an altered developmental phenotype and whether this correlates with their decreased activation status.
There has been some evidence to suggest that distant tumor growth alters the normal maturation of NK cells in the bone marrow. Using several subcutaneous tumor models (including EL4 thymoma, B16F1 melanoma, and 4T1 breast carcinoma), it has been shown that the number and maturity of NK cells is decreased in the bone marrow of tumor-bearing mice 13, 14 . These studies did not examine the phenotype of tumor-associated NK cells. In order to address this issue we utilized the spontaneous polyoma middle T antigen (pyMT) breast tumor model which allows us to study tumors which form naturally in a sequential fashion as well as to isolate NK cells directly from these tumors for phenotypic analysis 15 . We found that NK cells isolated from the tumors of pyMT mice have decreased expression of activation markers in comparison to peripheral splenic NK cells. Changes in activation correlated with changes in NK cell development as tumor-associated NK cells displayed low levels of DX5 and CD11b. Injection of CFSE-labeled mature NK cells into pyMT mice revealed that these cells were directly altered by the tumor microenvironment as those isolated from the spleen maintained their ability to be activated in contrast to those isolated from tumors. The developmental status of NK cells in pyMT tumors was quite plastic as treatment with IL-12 and anti-TGF-b promoted the NK cells to express increased markers of maturity. Our results reveal that the status of NK cell development is an important factor to examine when assessing the efficacy of NK cells in affecting tumor growth. In addition, NK cells are more adaptable than previously thought as treatment of tumors with IL-12 and anti-TGF-b has the ability to impact the maturation status of tumor-infiltrating NK cells.
MATERIALS AND METHODS

Mice
The spontaneous MMTV-pyMT transgenic mouse model is on a C57BL/6 background (breeding pairs provided by Dr Gendler, Mayo Clinic, Arizona). The mice develop spontaneous multifocal mammary carcinomas in all mammary glands. Mice were palpated weekly to follow tumor growth. Mice were bred and maintained at McMaster University's Central Animal Facility. Procedures comply with the guidelines set out by the Canadian Council on Animal Care.
Cell isolation from tumor tissues for flow cytometric analysis Tumors were removed from pyMT mice near endpoint (10 3 10 mm). Tumors were weighed and digested accordingly. A mixture of collagenase A (3 mg/mL) and DNase (0.025 mg/ml) (Roche Applied Science, Nutley, NJ) was prepared in Hanks media and filter sterilized (0.22 mM micropore). The tumors were diced and 10 mL of digestion mixture was added per gram of tumor. Tumors were digested for 45 minutes at 37 uC on a shaker. Cells were then filtered through 70 mM and 40 mM cell strainers. Red blood cells were lysed with ammonium-chloride-potassium (ACK) lysis buffer and cells were stained and analyzed by flow cytometry. All tumor samples were run on the BD LSR II flow cytometer.
Flow cytometric staining
Tumors were isolated from pyMT mice and processed as previously described. The following staining protocol was conducted on the processed tumors: cells plated in a 96-well Adoptive transfer of NK cells NK cells were isolated from spleens of C57BL/6 mice using a PE Selection Kit (STEMCELL Technologies) with the addition of 10 ml of anti-mouse NK1.1-PE antibody per 100 3 10 6 cells. Prior to isolation the spleens were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) as follows: splenocytes were washed two times with PBS and 2.5 mM of CFSE was added to 20 3 10 6 cells/mL. The cells were then incubated for 5 minutes at room temperature before being washed with CFSE two times with 310, the volume of PBS. After isolation, 4.5 3 10 6 CFSE1NK1.11 cells were injected intravenously into pyMT mice as well as a C57BL/6 mouse as a control. After three days, tumors and spleens were isolated, stained, and analyzed by flow cytometry. All tumor samples were run on the BD LSR II flow cytometer.
IL-12 and anti-TGF-b treatment in the spontaneous pyMT tumor model pyMT mice were palpated weekly to follow tumor growth. When at least two tumors reached 5 3 5 mm, intratumoral treatments were begun on each individual tumor. The treatments included 50 ng of IL-12 (Peprotech; catalog number: 210-12; biological activity: o1 3 10 7 units/mg; endotoxin level: ,0.1 ng/mg protein) and 50 mg of anti-TGF-b (Bio-X-Cell; catalog number: BE0086; biological activity: no data available; endotoxin: ,0.41 EU/mg) and a PBS control. Treatments were administered intratumorally in a total volume of 25 mL using a Hamilton syringe. Injections were administered every other day for a total of three days and mice were sacrificed on the following day to analyze the changes in the phenotype of the tumor-associated NK cells. Tumors and spleens from pyMT mice were isolated and cells were stained and analyzed by flow cytometry. All tumor samples were run on the BD LSR II flow cytometer.
Statistical analysis
Statistical analysis was performed with the use of Graph Pad Prism software (San Diego, CA). Any graphs which compared two conditions were analyzed using an unpaired student's t-test. Error bars represent standard error of the mean (SEM) and a p-value of less than 0.05 was interpreted to be statistically significant.
RESULTS
Tumor-associated NK cells from pyMT tumors are immature compared to their splenic counterparts
To determine the development of tumor-associated NK cells, we isolated tumors from pyMT mice near endpoint and stained them for NK cell-specific markers as well as CD27 and CD11b. To assess the phenotype of NK cells at a site distant to the tumor, we also isolated spleens from the same pyMT mice to assess NK cell maturity. Splenic NK cells were found at all stages of maturation, particularly in the later three stages: CD11b low CD27
high R CD11b high CD27 high R CD11b high CD27 low . In distinct contrast, NK cells isolated from within mouse breast tumors displayed an immature phenotype as evidenced by the increased proportion of CD11b low CD27 low NK cells ( Figure 1 ). Tumor-associated NK cells displayed very few cells at any other developmental stage, indicating that the tumor Tumor microenvironment alters NK cells T Krneta et al microenvironment greatly impacts the ability of these NK cells to fully mature or promotes the de-evolution of mature NK cells to a more immature state. In addition to the developmental phenotype acquired from the examination of CD11b and CD27 in combination, CD27 itself is a marker of NK cell cytotoxicity. In particular, CD27 plays an important role in NK cell activation as evidenced by the use of CD272/2 mice which display decreased cytolytic activity and cytokine production upon stimulation 16 . The expression of CD27 was significantly downregulated on NK cells isolated from tumors in comparison to those isolated from the spleens of the same mice ( Figure 1c) . As CD27 correlates with cytotoxicity, this indicates that their function is altered in addition to their maturity.
DX5 and CD11b have also been used in conjunction to assess the development of NK cells 14 . DX5 in particular is acquired late during development and is only expressed on mature NK cells 5 . In an effort to further characterize the developmental phenotype of tumor-associated NK cells, we isolated tumors and spleens from pyMT mice and stained them for NK cellspecific markers as well as DX5 and CD11b. Within the spleen, the majority of NK cells were mature as evidenced by their double positive expression of DX5 and CD11b (Figure 2 ). In contrast, tumor-associated NK cells displayed a decreased population of DX51CD11b1 NK cells and instead exhibited an increased expression of immature double negative NK cells. Immature NK cells have been shown to secrete very low levels of IFN-c and thereby have decreased killing abilities against YAC-1 target cells 17 . To ensure that the enzymatic procedure used for the isolation of NK cells from pyMT tumors did not affect the expression of cell surface antigens, freshly isolated splenocytes were incubated under the same enzymatic conditions and compared to those processed as normal. Overall, there were no significant differences between the normally processed spleens and those that underwent enzymatic digestion for the markers CD45, NK1.1, and CD3 ( Figure 3 ). While the DX51CD11b1 NK cell population decreased on average by 10%, it was determined that the enzymatic digestion could not have accounted for the decrease observed in this population in tumor-isolated NK cells from Figure 2 .
Tumor-associated NK cells from pyMT tumors have decreased expression of NKp46 and NKG2D
We next wanted to examine if NK cells from pyMT tumors have an altered level of activation markers in contrast to peripheral NK cells from tumor-bearing mice. NK cell recognition and subsequent destruction of tumor cells is controlled by a balance of activating and inhibitory receptors. Some of the main activating NK cell receptors include NKp46 and NKG2D, part of the natural cytotoxicity receptors (NCRs) group 18 . Ligands for activating receptors are often over- expressed on tumor cells and thus, they will be detected and killed by NK cells expressing activating receptors 19 . The ligand for NKG2D in mice is retinoic acid early inducible-1 (RAE-1) protein 20 . Ligands such as RAE-1 are not expressed on untransformed cells but are found to be upregulated on tumor cells undergoing stress due to DNA damage 21 . We therefore chose to examine the expression of NKp46 and NKG2D on NK cells isolated from the spleens and tumors of pyMT mice. We isolated and processed pyMT tumors and spleens and stained them for NK cell identification markers as well as NKp46 and NKG2D. We found that the expression of these cell surface markers was drastically reduced on tumor-associated NK cells, with very low expression of either NKp46 or NKG2D (Figure 4) . In addition to activating receptors, we also examined the functional NK cell markers perforin and granzyme B in the tumors of pyMT mice. The splenic NK cells, previously shown to be highly mature expressed high levels of perforin and granzyme B. On the other hand, immature intratumoral NK cells expressed these markers at a lower frequency. Perforin was expressed in only 10% of the intratumoral NK cells while granzyme B was expressed at a more intermediate level, in approximately 50% of intratumoral NK cells ( Figure 5 ). The downregulation of the activating markers NKp46 and NKG2D, as well as the functional markers perforin and granzyme B, implies that these NK cells are unable to impact tumor destruction in endpoint tumors in the pyMT model.
Immature NK cells have decreased levels of NKp46 and increased levels of NKG2A To determine if the increased numbers of immature NK cells in the tumors were also expressing low levels of activation receptors, we isolated pyMT spleens and tumors to examine both developmental and activation markers simultaneously. Gating on the DX51CD11b1 population in the spleen of pyMT mice revealed this population of cells expressed high levels of NKp46. In contrast, the DX52CD11b2 population expressed half the levels of NKp46 as the more mature subset, but greater levels of the inhibitory receptor NKG2A (Figure 6a) . Therefore, an increase in NK cell development corresponds to an increase in the ability of these cells to express the activation receptor NKp46, an important factor in tumor cell clearance 22 . In the context of a tumor microenvironment, however, even the small percentage of mature NK cells in the tumor were downregulated as they displayed drastically lower levels of NKp46 in comparison to the mature NK cells found within the spleen. Similar to the spleen, the DX52CD11b2 subset had increased levels of NKG2A (Figure 6b) . Therefore, there is a direct correlation between the proportion of immature NK cells found in the tumor and their inability to affect tumor growth. Tumor microenvironment alters NK cells T Krneta et al into pyMT mice. NK cells were purified from C57BL/6 spleens and 4.5 3 10 6 NK cells were intravenously injected into tumorbearing mice and a C57BL/6 control. Three days later, the mice were sacrificed and the phenotypes of the donor cells were examined by flow cytometry. We were able to detect CFSE1 NK cells in both the spleens and tumors of pyMT by flow analysis. Examination of the activation receptor NKp46 prior to and after transfer revealed that the expression of NKp46, which is highly expressed on splenic NK cells, was maintained when the NK cells were retrieved from the spleens of tumor-bearing mice (Figure 7) . However, the CFSE positive NK cells that were isolated from tumors expressed drastically reduced levels of NKp46. We also found that the cytotoxicity marker CD27, and the maturity marker DX5 were also decreased on tumor NK cells versus splenic NK cells in tumor-bearing mice ( Figure 7) . It is striking that after only three days of adoptive transfer, NK cells were able to home to the tumor and be impacted drastically by their microenvironment.
Treatment of pyMT tumors with IL-12 and anti-TGF-b increases the maturation of tumor-infiltrating NK cells
An important issue to examine is whether the immature population of NK cells found within pyMT tumors could be forced to mature by altering the tumor microenvironment. To modify the tumor microenvironment and shift the immune response toward tumor rejection, we chose to administer a combination of IL-12 and anti-TGF-b. In animal studies, it has been shown that use of an anti-TGF-b antibody restores NK cell activity and suppresses breast cancer metastasis 23 . In addition to inhibiting the immunosuppression within the tumor microenvironment, we aimed to administer a factor that could maximally activate NK cells and alter the environment in which they reside. It has been shown that IL-12 primes human NK cells to lyse tumor cells, induces DC maturation, and promotes M1 macrophage polarization through the release of IFN-c 24 . Previous treatment of tumors with IL-12 in vivo promoted anti-angiogenic activity and increased p53 activation, causing tumor suppression 25 . Figure 3 The enzymatic digestion procedure for the isolation of NK cells does not alter the expression of cell surface markers. Spleens were isolated from C57BL/6 and cut in half to be processed two ways: as normal and with an enzymatic digestion (incubated at 37 uC with the following digestion mixture: 3 mg/mL collagenase A and 0.025 mg/mL DNase I in Hanks). Both processed spleens were then stained for CD45, NK1.1, CD3, DX5, and CD11b. Analysis was conducted on five mice. suppression to activation, we used both of these factors in combination. pyMT mice were injected every other day for a total of three days with the combination of IL-12 and anti-TGF-b intratumorally. One day after the third injection, the mice were sacrificed and flow cytometric analysis was conducted to examine markers of NK cell maturation. PBS-treated mice maintained the immature phenotype previously observed in Figure 1 . However, after administration of three intratumoral injections of IL-12 anti-TGF-b, the NK cells became CD27 low CD11b high , a characteristic of mature NK cells (Figure 8 ). Although we did not continue treatment to follow the mice for survival, three treatments were enough to alter the tumor microenvironment and drive the NK cells to a more mature status. To our knowledge, this is the first evidence revealing that tumor-associated NK cells have a high degree of developmental plasticity and can be forced to mature and become activated with the hope of impacting tumor growth.
To drastically alter the tumor microenvironment from
DISCUSSION
Previous studies which have examined NK cells in the context of tumor development have described these cells as non-functional due to their lack of activation markers and increased expression of inhibitory receptors 12, [26] [27] [28] . In the context of our work, we believe that these cells are not necessarily nonfunctional but are at a different stage in their development within tumors. They are still fully capable of maturing and performing their cytotolytic functions if activated by outside stimulatory factors. We report here that in the tumors of pyMT mice, NK cells had a CD27 low CD11b low immature phenotype as well as decreased expression of DX5. In a study examining human NK cells, this immature double negative subset was found to produce the lowest levels of IFN-c and TNF-a compared to the CD11b low CD27 high and CD11b high CD27 high subsets, which had the highest expression of these two cytokines. It was therefore concluded that NK cells acquire the ability to produce cytokines during their development. While the CD11b high CD27 low population secreted lower levels of cytokines compared to the intermediate developmental stages, it was found that they still secreted more than the immature double negative subset. It was also concluded in this study that the immature double negative subset had the lowest cytolytic activity of the four subsets and that cytolytic activity increases with increasing NK cell development 9 . It makes sense therefore, that in our study we found the highest amounts of CD27 low CD11b low NK cells within pyMT tumors as these cells produce the lowest levels of IFN-c and TNF-a, are the least cytotoxic, and allow the tumor to continue to grow.
In addition, we also found that tumor-associated NK cells had significantly decreased expression of NKG2D, NKp46, perforin, and granzyme B as well as increased expression of the inhibitory receptor NKG2A. The results we have examined in murine tumor-associated NK cells correlate well with human studies which have shown that NK cells from human cervical tumors or non-small cell lung carcinoma (NSCLC) display decreased expression of NKp46 and NKG2D 29, 30 . In these studies, tumor NK cells were less cytotoxic and displayed a reduced ability to produce IFN-c.
To correlate the decreased activation markers on tumorassociated NK cells with their altered development, we gated on the CD11b2DX52 population to reveal the expression of NKp46 and NKG2A on immature NK cells. We found that this population highly expressed NKG2A and had decreased expression of NKp46. This led us to conclude that the maturation status of NK cells within tumors correlated with their activation potential as well. Others have also described that the acquisition of NKp46 serves as a marker for NK cell maturity 31 . NK cells at a peripheral site such as the spleen did not have the same altered developmental phenotype that we saw in the tumors of pyMT mice. This led us to examine if the microenvironment of the tumor specifically alters NK cells. To do this we adoptively transferred labeled NK cells into pyMT mice. These cells were taken from C57BL/6 spleens and therefore prior to transfer, were fully mature and functional in their Figure 7 After adoptive transfer of NK cells, there is decreased NK cell activation in the tumor but not in the spleen of tumor bearing mice. NK cells were isolated from spleens of C57BL/6 mice using a PE Selection Kit (STEMCELL Technologies TM ). Prior to isolation the spleens were stained with CFSE for ease of detection post transfer. 4.5 x 10 6 CFSE+ NK1.1+ cells were injectedi.v .into pyMT mice as well as a C57BL/6 mouse as a control. After three days, tumors and spleens were isolated and stained for NKp46, CD27, and DX5. NK cells were gated as CFSE+. Analysis was conducted on 3 mice. (A) CFSE+ NK cells isolated from the spleen and tumor (B) NKp46, CD27, and DX5 analyzed by flow cytometry and (C) quantified. (Representative of 2 separate experiments. Results were analyzed by student's t-test. ***P , 0.001, **P , 0.01, *P , 0.05.) expression of activation receptors. If we saw no difference in the development of the transferred NK cells within the tumors, we could conclude that the tumor recruits already immature NK cells from the bone marrow. However, we found the opposite to occur. Once in the mouse, NK cells that traveled to the spleen maintained their expression of NKp46, while those that traveled to the tumor, had significantly decreased expression of NKp46 within three days after transfer. Others have shown similar phenomena to occur in adoptive transfer models of NK cells after two weeks of transfer. NK cells transferred to tumor-bearing mice were able to rapidly home to and accumulate within tumors; however, they were unable to effect tumor growth 32 . After re-isolation from the tumor, NK cells were tested for their functional capacity and found to produce less IFN-c and have reduced cytolytic activity. They found this exhausted phenotype to be accompanied by downregulation of the transcription factors Eomesodermin and T-bet 32 . The mechanism responsible for the alteration in activation and maturity of tumor-associated NK cells is unknown. Richards et al. have shown that NK cells in the bone marrow of tumor-bearing mice also have an immature phenotype 14 . In their subcutaneous tumor models, there was very little tumorcell infiltrate in the bone marrow, leading them to conclude that this defect was not due to a tumor-cell mechanism. Instead they found that the defect was associated with a reduction in the percentage of cells expressing IL-15Ra in the bone marrow 14 . Due to the fact that the developmental defect we observed in pyMT mice was specific to the tumor, we believe that the altered NK cell phenotype is directly related to the immunosuppressive cytokines and cells found within that particular microenvironment. Several studies have indicated that TGF-b produced in the tumor can decrease NK cell cytotoxicity and cytokine secretion 12, 33 . In human studies, it was found that TGF-b affects the development of NK cells in the blood by inhibiting their development and converting a small fraction of CD56 bright CD161 NK cells into CD56 bright CD162 NK cells 34 . In our model, TGF-b may also play a role in the altered maturation we observed as neutralization within the tumor did cause tumor-associated NK cells to mature in combination with IL-12. It would be important for future studies to examine if one or a combination of factors is responsible for altering the development of NK cells specifically at the tumor site.
It is beneficial that the phenotype of tumor-associated NK cells can be reversed upon treatment of tumors. We chose treatment with IL-12 and anti-TGF-b and have shown that this combination alters the NK cells to a more mature state. To our knowledge, this combination of factors has not been tested for efficacy in cancer models. However, in a model of Leishmania major infection, combined treatment with IL-12 and anti-TGFb antibody was found to shift the balance of cytokine production from Th2 to Th1, revealing that inhibiting TGF-b may amplify the responses normally seen during IL-12 treatment 35 . Our results argue that NK cells are more adaptable than previously thought. Overall, the data suggest that if we promote the development of NK cells in tumors, they could have greater impact on tumor destruction. To gain a better understanding of tumor-associated NK cells, it would be beneficial to perform gene expression analyses on the cells in order to define their unique phenotype and roles within the tumor. Loza et al. have shown that IFN-c is acquired late during NK cell development while IL-13 is produced by immature NK cells 36 . If immature NK cells produce factors such as IL-13, which skew the immune response to a Th2 bias, they might add to the immunosuppressive environment of the tumor. Several recent studies have been done on tumoral NK cells in NSCLC patients. It was found that NK cells from human NSCLC tumors are CD56 bright CD162 and promote angiogenesis by producing vascular endothelial growth factor, placental grow factor, and IL-8 37 . This is similar to the functions that have been reported for uterine NK cells 38 . In addition, in these human tumors and in mouse models of this tumor type, it was found that CD272CD11b2 immature NK cells also predominated and actually correlated with tumor progression 39 . Further examination of why tumors force NK cells to become immature and how this might be beneficial to their growth are required. In addition, these recent studies indicate that NK cells in tumors may actually support tumor growth.
The plasticity of NK cell responses is a double-edged sword. It provides hope that if we change the signals in the tumor, we could allow for the activation and development of NK cells, effective killers against tumors. Unfortunately, it also means that the tumor may be easily able to convert activated NK cells to an immature, un-activated, or possibly pro-tumoral state. Studies such as this will help us design more effective NK cell adoptive transfer or cytokine therapies aimed at generating NK cell anti-tumor immune responses. From our results, it can be concluded that examining the status of NK cell development can give researchers additional information as to whether these cells have the potential to slow tumor growth.
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